A unique rat liver hilar clamp model was developed for studying the impact of pharmacologic molecules in ameliorating ischemia-reperfusion injury. This model includes direct cannulation of the portal supply to the ischemic liver segment via a branch of the portal vein, allowing for direct hepatic delivery.
Major hepatic surgery with inflow occlusion, and liver transplantation, necessitate a period of warm ischemia, and a period of reperfusion leading to ischemia/reperfusion (I/R) injury with myriad negative consequences. Potential I/R injury in marginal organs destined for liver transplantation contributes to the current donor shortage secondary to a decreased organ utilization rate. A significant need exists to explore hepatic I/R injury in order to mediate its impact on graft function in transplantation. Rat liver hilar clamp models are used to investigate the impact of different molecules on hepatic I/R injury. Depending on the model, these molecules have been delivered using inhalation, epidural infusion, intraperitoneal injection, intravenous administration or injection into the peripheral superior mesenteric vein. A rat liver hilar clamp model has been developed for use in studying the impact of pharmacologic molecules in ameliorating I/R injury. The described model for rat liver hilar clamp includes direct cannulation of the portal supply to the ischemic hepatic segment via a side branch of the portal vein, allowing for direct segmental hepatic delivery. Our approach is to induce ischemia in the left lateral and median lobes for 60 min, during which time the substance under study is infused. In this case, pegylated-superoxide dismutase (PEG-SOD), a free radical scavenger, is infused directly into the ischemic segment. This series of experiments demonstrates that infusion of PEG-SOD is protective against hepatic I/R injury. Advantages of this approach include direct injection of the molecule into the ischemic segment with consequent decrease in volume of distribution and reduction in systemic side effects.
Major hepatic surgery with inflow occlusion, and liver transplantation, necessitate a period of warm ischemia, and a period of reperfusion leading to ischemia/reperfusion (I/R) injury1. The consequences of I/R injury in the liver have been detailed extensively1,2,3. Consequences of I/R injury detailed in the literature include: generation of reactive oxygen species, initiation of the inflammatory cascade including activation of neutrophils, Kupffer cells, and endothelial cells, activation of the heme oxygenase system and activation of toll-like receptors, an imbalance between endothelin and nitric oxide, activation of nuclear factor-κB, and promotion of proinflammatory cytokine and adhesion molecule synthesis1,2,3. These proinflammatory events may lead to apoptosis, necrosis, organ dysfunction and eventual organ failure3.
I/R injury in organs destined for liver transplantation can lead to early graft loss and contributes to the current donor shortage as marginal organs are more susceptible to injury3. There are currently 15,226 potential recipients on the waiting list for liver transplantation in the United States4 and only 5,950 liver transplants were performed in 20155. Due to this extreme limitation in organ availability, research exploring hepatic I/R injury is needed in order to optimize graft function and organ utilization.
Animal models used to study hepatic I/R injury include rat hilar clamp models and rat liver transplantation models. There are a variety of rat hilar clamp models currently in use. The most common is one in which the portal vein, hepatic artery and bile duct supplying the left lateral and median lobes are clamped using microsurgical clips6,7,8,9,10,11,12 for 30 to 60 min6,7,10,13,14, and then a period of reperfusion from 60 min to 24 h7,9,10,13,14 is allowed. The left lateral and median lobes of the rat liver comprise about 70% of the hepatic parenchyma9. Some protocols designed to study ischemic preconditioning include intermittent clamping of the hilar vessels or the hind-limb prior to a longer period of ischemia induced by clamping the hilar vessels9,13. There are also several modifications described in the literature. The first is to clamp the portal vein and hepatic artery supplying the left lateral and median lobes, but exclude the bile duct15. A second modification is to induce total hepatic ischemia by clamping the portal vein, hepatic artery and bile duct prior to their division16,17,18,19,20. A third modification includes clamping of the hilar vessels to the right lobe for 30 to 60 min8. An additional modification involves clamping the vascular bundle in one hind limb in order to induce injury in the liver13,21. Various approaches to the hilar clamp procedure are illustrated in Figure 1A-D.
Rat liver hilar clamp models have been used to study the impact of different molecules and compounds on hepatic I/R. Depending on the model used these molecules have been delivered using inhalation11, epidural infusion12, intraperitoneal injection17,18,21,22, intravenous administration10,14,15,19,23,24 or injection into the peripheral superior mesenteric vein8.
The model for rat liver hilar clamp detailed in this report includes direct cannulation of the portal supply to the ischemic segment via a side branch of the portal vein (Figure 2), which allows for direct segmental hepatic delivery of the pharmacological substance under study. Our approach is to induce ischemia in the left lateral and median lobes for 60 min, during which time an infusion of the substance under study, in this case, pegylated-superoxide dismutase, a free radical scavenger25, is infused directly into the ischemic segment. Blood samples are taken prior to induction of ischemia and at 120 min post-reperfusion. At this point, the rat is sacrificed and samples are taken from the left and median lobes. Additionally, samples are taken from the right lobe to serve as an internal control.
There are numerous advantages to this approach. First and foremost, when the pharmacologic substance under study can be directly injected into the ischemic segment the volume of distribution is quite low in comparison to the volume of distribution of injection into the systemic circulation or the peritoneal cavity. Additionally, this approach reduces, although does not eliminate, the possibility of systemic side effects.
All procedures were performed according to the guidelines of the Institutional Animal Care and the National Research Council's Guide for the Humane Care and Use of Laboratory Animals (IACUC) and has undergone approval by the Ohio State University IACUC committee.
1. Initial Set-up
2. Induction of Anesthesia
3. Procedure
4. Monitoring
5. Reperfusion
6. Continued Sampling
7. Euthanasia
8. Post-experiment Analysis
This experiment was performed with 2 groups of n = 3 rats each. Three rat livers were injected with 2 mL of normal saline (NS) with the infusion pump over a period of 15 min. Three rat livers were injected with 2 mL of normal saline (NS) mixed with pegylated-superoxide dismutase (PEG-SOD, 0.00067 g/mL) with the infusion pump over a period of 15 min. As described in the above protocol, blood samples were taken pre-hilar clamp and at 120-min post-reperfusion. Additionally, after completion of 120-min of reperfusion four liver tissue samples were taken from the left and median lobes and four liver samples were taken from the right lobe of the rat liver.
Serum Alanine Aminotransferase (ALT) was measured pre-hilar clamp and at 120-min post-reperfusion in control (NS) and experimental (PEG-SOD) animals. There was a significant difference between the ALT level of control (NS) animals pre-hilar clamp and at 120-min post-reperfusion. There was a significant difference between ALT level of control (NS) and experimental animals (PEG-SOD) at 120-min (Figure 13A). Tissue malonaldehyde (MDA) was measured for control (NS) and experimental (PEG-SOD) animals in both right and left lobes of the liver. Tissue MDA in right lobe (non-hilar clamp) with control injection (NS) and experimental injection (PEG-SOD) demonstrate no significant difference. Left lobe (post-hilar clamp and reperfusion) tissue MDA with control injection (NS) is significantly different than right lobe (non-hilar clamp) p < 0.001. Left lobe (post-hilar clamp and reperfusion) has significantly different levels of tissue MDA with control injection (NS) versus experimental injection (PEG-SOD) p < 0.005 (Figure 13B). Tissue glutathione (GSH) was measured and tissue glutathione in right lobe (non-hilar clamp) with control injection (NS) and experimental injection (PEG-SOD) demonstrate no significant difference. Left lobe (post-hilar clamp and reperfusion) tissue GSH with control injection (NS) is significantly different than right lobe (non-hilar clamp) with control injection (NS) p < 0.05. Left lobe (post-hilar clamp and reperfusion) has significantly different levels of tissue glutathione with control injection (NS) versus experimental injection (PEG-SOD) p < 0.005 (Figure 13C). Western blot was performed comparing right and left lobe of control animals and demonstrates increased cleaved caspase-3 in the left lobe after hilar clamp and reperfusion (Figure 13D). A second western blot was performed comparing the left lobes of animals treated with control and with PEG-SOD (Figure 13E). This demonstrates decreased cleaved caspase-3 in the liver tissue of animals treated with PEG-SOD. Densitometry was also performed demonstrating that the level of cleaved caspase-3 in liver tissue is significantly increased in the left versus right lobe of control animals (Figure 13F). In comparing the left lobe liver tissue of experimental animals, infused with PEG-SOD, and left lobe liver tissue of control animals, infused with Normal Saline, densitometry demonstrates significantly decreased cleaved caspase-3 in animals treated with PEG-SOD in comparison to animals treated with control (Figure 13G).
Figure 1: Anatomical Illustrations. A. Anatomical illustration of the rat liver. B. Anatomical illustration of the rat liver. The portal pedicle to the left and median lobes of the liver is clamped. The left and median lobes are ischemic. C. Anatomical illustration of the rat liver. The portal pedicle to the left lobe is clamped. The left lobe is ischemic. D. Anatomical illustration of the rat liver. The portal pedicle to the right lobe is clamped and the right lobe is ischemic.
Figure 2: Anatomical Illustrations. Anatomical illustration of the rat liver with portal vein cannulated via a side branch. The portal pedicle to the left and median lobes of the liver is surrounded by a suture and a microvessel clamp has been used to tighten around the vascular bundle. The left and median lobes are ischemic.
Figure 3: Instrument Set-up. This figure demonstrates the instrument set-up.
Figure 4: Operating Room Set-up. This figure demonstrates the operating room set-up. Please click here to view a larger version of this figure.
Figure 5: Trimming of Abdominal Hair. This figure demonstrates the trimming of the abdominal hair. Please click here to view a larger version of this figure.
Figure 6: Immobilization and Skin Incision. This figure demonstrates the immobilization of the rat and the skin incision. Please click here to view a larger version of this figure.
Figure 7: Rib Retractor Placement and Evisceration. This figure demonstrates the rib retractor placement and evisceration. Please click here to view a larger version of this figure.
Figure 8: Placement of Suture. This figure demonstrates the placement of the suture. Please click here to view a larger version of this figure.
Figure 9: Blood Draw from the Inferior Vena Cava. This figure demonstrates blood draw from the inferior vena cava. Please click here to view a larger version of this figure.
Figure 10: Vein Branch Tied Off and Retracted. This figure demonstrates vein branch tied off and retracted. Please click here to view a larger version of this figure.
Figure 11: Process of Cannulation. This figure demonstrates the process of cannulation. Please click here to view a larger version of this figure.
Figure 12: Cannulation. This figure demonstrates the cannulation. Please click here to view a larger version of this figure.
Figure 13: Representative Results: Direct Segmental Intrahepatic Delivery of Pegylated-Superoxide Dismutase Using a Rat Hilar Clamp Model. NS = normal saline. PEG-SOD = pegylated-superoxide dismutase, ALT = alanine aminotransferase, MDA = malondialdehyde. A. Serum Alanine Aminotransferase (ALT, mU/mL) compared between pre-hilar clamp and 120-min post-reperfusion. There is a significant difference between control (NS) pre-hilar clamp and control (NS) at 120-min post-reperfusion (p < 0.001). There is also a significant difference between control (NS) and experimental groups (PEG-SOD) at 120-min post-reperfusion (p < 0.05). A student's T-test was used. Error bars represent standard deviation. B. Tissue malondialdehyde in right lobe (non-hilar clamp) with control injection (NS) and experimental injection (PEG-SOD) demonstrate no significant difference. Left lobe (post-hilar clamp and reperfusion) tissue malondialdehyde with control injection (NS) is significantly different than right lobe (non-hilar clamp) p < 0.001. Left lobe (post-hilar clamp and reperfusion) has significantly different levels of tissue malonaldehyde with control injection (NS) versus experimental injection (PEG-SOD) p < 0.005. A student's T-test was used. Error bars represent standard deviation. C. Tissue glutathione in right lobe (non-hilar clamp) with control injection (NS) and experimental injection (PEG-SOD) demonstrate no significant difference. Left lobe (post-hilar clamp and reperfusion) tissue glutathione with control injection (NS) is significantly different than right lobe (non-hilar clamp) with control injection (NS) p < 0.05. Left lobe (post-hilar clamp and reperfusion) has significantly different levels of tissue glutathione with control injection (NS) versus experimental injection (PEG-SOD) p < 0.005. A student's T-test was used. Error bars represent standard deviation. D. Western blot demonstrating increased cleaved caspase-3 in liver tissue of the left lobe (post-hilar clamp and reperfusion) versus the right lobe (non-hilar clamp) of control animals (Normal Saline). E. Western blot demonstrating decreased cleaved caspase-3 in liver tissue of animals treated with PEG-SOD in comparison to animals treated with control (Normal Saline). F. Level of cleaved caspase-3 in liver tissue is significantly increased in post-hilar clamp and reperfusion animals (p < 0.05). A student's T-test was used. Error bars represent standard deviation. G. In comparing left lobe liver tissue of experimental animals (infused with PEG-SOD) and left lobe liver tissue of control animals (infused with Normal Saline), there is significantly decreased cleaved caspase-3 in animals treated with PEG-SOD in comparison to animals treated with control (Normal Saline). A student's T-test was used. Error bars represent standard deviation.
This series of experiments demonstrated that injection of PEG-SOD into the left and median lobes led to significant decreases in the release of ALT, lipid peroxidation of cell membranes (MDA), and maintenance of glutathione (GSH) when compared with controls (Normal Saline). Liver tissue transaminases including Alanine Aminotransferase (ALT) are established markers of hepatocellular injury. The decrease in ALT when the left lobe is injected with PEG-SOD suggests a protective effect of PEG-SOD. Increased tissue MDA indicates increased lipid peroxidation and is considered a marker of oxidative stress and tissue injury. Overproduction of reactive oxygen species causes an increase in production of MDA26. The significant reduction in tissue MDA in the animal's left and median lobes when injected with PEG-SOD demonstrates a protective effect of PEG-SOD. This is consistent with the current understanding that PEG-SOD protects cells from damage caused by partially reduced reactive oxygen species27. Additionally, in the presence of reactive oxygen species, glutathione disulfide is reduced to glutathione (GSH)28. The maintenance in GSH in the left and median lobes of the liver injected with PEG-SOD further reinforces the protective effect of PEG-SOD. Additionally it is demonstrated that there is increased cleaved caspase-3, a product of apoptosis, in tissue exposed to ischemia-reperfusion injury. The decrease in cleaved caspase-3 in the left lobe when treated with PEG-SOD suggests that PEG-SOD leads to a decrease in apoptosis.
Superoxide dismutase (SOD) is a critical enzyme in the detoxication of reactive oxygen species. The enzyme catalyzes the conversion of two superoxide anions into hydrogen peroxide and water. The enzyme catalase then converts hydrogen peroxide to water and oxygen, completing the process25. The half-life of native SOD limited its use in experimental models until the development of conjugated polyethylene glycol-superoxide dismutase (PEG-SOD). Conjugation of SOD to polyethylene glycol increases its half-life from 6 min to 14 h. Nguyen et al. demonstrated its ability to mitigate lipid peroxidation in hepatic ischemia in a rat model, using systemic delivery29.
There are a variety of potential modifications of the technique detailed here and some have previously been described in the literature. Depending on the model used molecules have been delivered using inhalation11, epidural infusion12, intraperitoneal injection17,18,21,22, intravenous administration10,14,15,19,23,24 or injection into the peripheral superior mesenteric vein8.
There are several critical steps in this protocol. The most important is the cannulation of the portal vein. Care must be taken that the hole cut in the vein is not too large. The tissue is very elastic and the hole will enlarge on its own. We recommend starting by cutting a hole that is 0.5 mm with the microsurgical scissors. The cannula can be fed through the hole using an instrument, which allows for greater agility than if trying to perform this portion of the procedure by hand. Additionally, while initially feeding the cannula, it should be aimed directly towards the bifurcation of the left and right portal veins to avoid poking a hole through the back wall of the vein. When the cannula tip reaches the bifurcation, it can then be fed into the left vein specifically. Once the cannula is fed into the left portal vein, which supplies both the left and median lobes, its position can be confirmed manually by feeling it inside the vein. Its position can also be confirmed by injecting a small amount of cold saline and seeing the blanching effect on the supplied segments of the liver.
The liver hilar clamp model in the rat provides a reproducible and stable platform for demonstrating hepatic ischemic-reperfusion injury. Variable hilar clamp models have been used by researchers to study the protective effects of anti-oxidants and other small molecules6,7,8,9,10,11,12,13,14. Points of variation include which vessels are clamped, which segment are made ischemic, whether or not the bile duct is included and the length of the period of reperfusion6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21. Additionally, when this model is used to study the impact of administration of a molecule the route of administration is also heterogeneous8,10,11,12,14,15,17,18,19,21,22,23,24. There are several advantages to the described approach. First, direct cannulation of the portal supply to the ischemic segment allows for direct segmental hepatic delivery of the pharmacological substance under study. This allows utilization of the other lobes of the livers as an internal control. Second, segmental hepatic cannulation allows for a reduced volume of distribution for the molecule being studied. This approach thereby reduces the risk of systemic side effects as the substance is injected directly into the liver segment of interest. Direct cannulation of the hepatic segment allows for the substance to be delivered pre-ischemia, intra-ischemia or post-ischemia. This allows for study of the molecule's effect at any point in the ischemia-reperfusion injury cycle. With increased length of ischemic time and increased level of injury additional opportunity to study liver regeneration would be available.
There are also some limitations of this approach. The first is start-up cost. The purchase of a surgical microscope could be a significant start-up cost for a lab that does not already possess one. This technique may be difficult or impossible without a microscope. The second is learning curve time. Although this procedure is relatively simple it does require some practice and it is likely that a novice will require a significant number of procedures to become an expert.
In summary, this model allows for a reproducible, simple, and cost-effective platform to study hepatic ischemia-reperfusion injury. Although in the protocol described here polyethylene glycol-superoxide dismutase, a free radical scavenger25, was infused, this model could be used to infuse a variety of different pharmacologic substances in order to evaluate their impact on I/R injury in the liver.
The authors have nothing to disclose.
We would like to acknowledge Dennis Mathias for his illustrative work. This work was supported by NIH T32AI 106704-01A1 and the T. Flesch Fund for Organ Transplantation, Perfusion, Engineering and Regeneration at The Ohio State University.
Sprague-Dawley Rat | Harlan Sprague Dawley Inc. | 200- 250 grams | |
Surgical Microscope | Leica | M500-N w/ OHS | |
Charcoal Canisters | Kent Scientific | SOMNO-2001-8 | |
Isoflurane Molecular Weight 184.5 | Piramal Healthcare | ||
Pressure-Lok Precision Analytical Syringe | Valco Instruments Co, Inc. | SOMNO-10ML | |
Electrosurgical Unit | Macan | MV-7A | |
Warming Pad | Braintree Scientific | HHP2 | |
SomnoSuite Small Animal Anesthesia System | Kent Scientific | SS-MVG-Module | |
PhysioSuite | Kent Scientific | PS-MSTAT-RT | |
Isoflurane chamber | Kent Scientific | SOMNO-0530LG | |
SurgiVet | Isotec | CDS 9000 Tabletop | |
Oxygen | Praxair | 98015 | |
27-0 Micro-Cannula | Braintree Scientific | MC-28 | |
Rib retractors | Kent Scientific | INS600240 | |
Polyethylene Glycol – Superoxide Dismutase (PEG-SOD) | Sigma Aldrich | S9549 SIGMA | |
GenieTouch | Kent Scientific | ||
Normal Saline | Baxter | NDC 0338-0048-04 | |
4×4 Non-Woven Sponges | Criterion | 104-2411 | |
Sterile Q-Tips | Henry Schein Animal Health | 1009175 | |
U-100 27 Gauge Insulin Syringe | Terumo | 22-272328 | |
5mL Syringe | BD | REF 309603 | |
4-0 Braided Silk Suture | Deknatel, Inc. | 198737LP | |
7-0 Braided Silk Suture | Teleflex Medical | REF 103-S | |
1.8 mL Arcticle Cryogenic Tube | USA Scientific | 1418-7410 | |
Microsurgical Instruments | |||
Name | Company | Catalog Number | Comments |
Small Scissors | Roboz | RS-5610 | |
Large Scissors | S&T | SAA-15 | |
Forceps – Large Angled | S&T | JFCL-7 | |
Forceps – Small Angled | S&T | FRAS-15 RM-8 | |
Clip Applier | ROBOZ | RS-5440 | |
Scissors – non micro | FST 14958-11 | 14958-11 | |
Forceps – Straight Tip | S&T | FRS-15 RM8TC | |
Large Microsurgical Clip | Fine Scientific Tools | 18055-01 | |
Small Microsurgical Clip | Fine Scientific Tools | 18055-01 | |
Small Microsurgical Clip | Fine Scientific Tools | 18055-02 | |
Small Microsurgical Clip | Fine Scientific Tools | 18055-03 | |
Other Instruments | |||
Name | Company | Catalog Number | Comments |
Small Mosquito Clamps | Generic | ||
Analysis | |||
Name | Company | Catalog Number | Comments |
Alannine aminotransferase (ALT) assay | Biovision | K752-100 | |
Malondialdehye (MDA) assay | Abcam | ab118970 | |
Glutathione (GSH) assay | Cayman Chemical | 7030002 | |
Antibodies – Cleaved Caspase-3 and Actin | Cell Signaling Tecnology | Antibody 9661 | |
ImageJ Software | National Institutes of Health | ||
RIPA Lysis and Extraction Buffer | Millipore | 10-188 |